Akebia Therapeutics, Inc. (AKBA): Nasdaq/NYSE listing notice — Akebia receives Nasdaq deficiency notice for late Q2 filing; plans to file by Aug 25

Akebia Therapeutics, Inc.

Form 10-Q for Q2 2023 not filed on time; Nasdaq gave non-compliance notice on Aug 11, 2023.
Accounting errors identified regarding return reserves for Auryxia in prior financial statements.
Company has 60 days to submit a plan; expects to file Form 10-Q by August 25, 2023.
Common stock continues trading on Nasdaq; Akebia expects to regain compliance upon filing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Akebia Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 11, 2023, Akebia Therapeutics, Inc. (the “Company”) received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “Quarterly Report”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”). The Nasdaq notification letter specifies that the Company has 60 calendar days

View on SEC.gov

Browse all listing & compliance notices →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.